Plain-English translation of NCT02347111 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Atrial fibrillation is a common heart rhythm disorder that increases your risk of stroke and other serious complications. This trial is testing whether your genetic makeup can help doctors predict whether or will work better for you. The study will help researchers understand why some people respond well to one medication while others don't.
Currently, doctors use a 'one-size-fits-all' approach when choosing heart rhythm medications, but more than half of patients see their symptoms return within 6 to 12 months. This trial aims to discover whether genetic testing can help predict which medication will actually work for each individual patient, leading to more personalized and effective treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to start with one of two medications for 6 months, then switch to the other medication for another 6 months. During the study, you'll have clinic visits to monitor how well each medication controls your heart rhythm and check for side effects. Researchers will also take a blood sample to analyze your genes and determine whether your genetic profile predicts which medication worked better for you.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States